SG11201604565WA - Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same - Google Patents
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using sameInfo
- Publication number
- SG11201604565WA SG11201604565WA SG11201604565WA SG11201604565WA SG11201604565WA SG 11201604565W A SG11201604565W A SG 11201604565WA SG 11201604565W A SG11201604565W A SG 11201604565WA SG 11201604565W A SG11201604565W A SG 11201604565WA SG 11201604565W A SG11201604565W A SG 11201604565WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- same
- chimeric antigen
- antigen receptors
- specific chimeric
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361912948P | 2013-12-06 | 2013-12-06 | |
US201461991697P | 2014-05-12 | 2014-05-12 | |
PCT/US2014/063096 WO2015084513A1 (en) | 2013-12-06 | 2014-10-30 | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201604565WA true SG11201604565WA (en) | 2016-07-28 |
Family
ID=51946020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201604565WA SG11201604565WA (en) | 2013-12-06 | 2014-10-30 | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
Country Status (8)
Country | Link |
---|---|
US (2) | US10676528B2 (zh) |
EP (1) | EP3077416B1 (zh) |
JP (2) | JP6943568B2 (zh) |
CN (1) | CN105899531B (zh) |
CA (1) | CA2932424C (zh) |
RU (1) | RU2701346C1 (zh) |
SG (1) | SG11201604565WA (zh) |
WO (1) | WO2015084513A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017205747A1 (en) | 2016-05-27 | 2017-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Flt3-specific chimeric antigen receptors and methods using same |
EP3507304B1 (en) * | 2016-09-02 | 2024-04-03 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
CA3057999A1 (en) * | 2017-04-04 | 2018-10-11 | Loma Linda University | Biologic for the treatment of cancer |
CN110526985A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向egfr的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
CN111632135A (zh) * | 2020-05-09 | 2020-09-08 | 深圳宾德生物技术有限公司 | 靶向nkg2d的嵌合抗原受体t细胞在治疗前列腺癌中的应用、治疗前列腺癌的药物 |
EP4168029A1 (en) * | 2020-06-19 | 2023-04-26 | Board of Regents, The University of Texas System | Anti-bst2 antibodies targeting bst2 long isoform |
EP4168437A1 (en) | 2020-06-22 | 2023-04-26 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
WO2023028612A2 (en) * | 2021-08-27 | 2023-03-02 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
IN165717B (zh) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
PT2077279E (pt) | 2000-06-28 | 2012-09-14 | Amgen Inc | Moléculas do receptor de linfopoietina estromal tímica e suas utilizações |
GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
CA2671538A1 (en) | 2006-12-14 | 2008-06-26 | Leonard G. Presta | Engineered anti-tslp antibody |
CA2713935C (en) | 2008-02-07 | 2016-11-01 | Schering Corporation | Engineered anti-tslpr antibodies |
CA2768552A1 (en) * | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
CN106220739A (zh) * | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
US20150010475A1 (en) | 2011-12-30 | 2015-01-08 | Stc.Unm | Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all) |
EP2802599B1 (en) | 2012-01-09 | 2019-09-04 | Yeda Research and Development Co. Ltd. | Anti-inflammatory peptides and use thereof |
AU2013221672B2 (en) * | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
ES2824024T3 (es) * | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
CN111139256A (zh) * | 2013-02-20 | 2020-05-12 | 诺华股份有限公司 | 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症 |
EP3858378A1 (en) * | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
WO2015118124A1 (en) * | 2014-02-06 | 2015-08-13 | Vib Vzw | Thymic stromal lymphopoietin receptor antagonist |
EP3507304B1 (en) | 2016-09-02 | 2024-04-03 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
-
2014
- 2014-10-30 RU RU2016124670A patent/RU2701346C1/ru active
- 2014-10-30 EP EP14802259.3A patent/EP3077416B1/en active Active
- 2014-10-30 CN CN201480072437.4A patent/CN105899531B/zh active Active
- 2014-10-30 SG SG11201604565WA patent/SG11201604565WA/en unknown
- 2014-10-30 CA CA2932424A patent/CA2932424C/en active Active
- 2014-10-30 WO PCT/US2014/063096 patent/WO2015084513A1/en active Application Filing
- 2014-10-30 JP JP2016536812A patent/JP6943568B2/ja active Active
- 2014-10-30 US US15/101,583 patent/US10676528B2/en active Active
-
2020
- 2020-04-28 US US16/860,216 patent/US11834509B2/en active Active
-
2021
- 2021-05-21 JP JP2021086485A patent/JP7100177B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3077416B1 (en) | 2019-06-19 |
US20200308289A1 (en) | 2020-10-01 |
JP2017501143A (ja) | 2017-01-12 |
CN105899531B (zh) | 2022-02-25 |
WO2015084513A1 (en) | 2015-06-11 |
JP7100177B2 (ja) | 2022-07-12 |
CA2932424C (en) | 2023-10-10 |
RU2701346C1 (ru) | 2019-09-25 |
JP2021138724A (ja) | 2021-09-16 |
EP3077416A1 (en) | 2016-10-12 |
JP6943568B2 (ja) | 2021-10-06 |
US20160311910A1 (en) | 2016-10-27 |
RU2016124670A (ru) | 2018-01-10 |
CN105899531A (zh) | 2016-08-24 |
CA2932424A1 (en) | 2015-06-11 |
US11834509B2 (en) | 2023-12-05 |
US10676528B2 (en) | 2020-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272279A (en) | Chimeric antigen receptor and methods of using it | |
IL289883A (en) | Directed t cells containing chimeric antigen receptors specific for cd123 and a method for using them | |
IL263626A (en) | Chimeric antigen receptors and methods for use | |
HK1224332A1 (zh) | 人類間皮素嵌合性抗原受體及其用途 | |
SG11201604565WA (en) | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same | |
HK1222186A1 (zh) | 嵌合抗原受體 | |
HK1222679A1 (zh) | 特異性嵌合抗原受體及其用途 | |
AU2015269219B2 (en) | Mesothelin-targeted chimeric antigen receptors and uses thereof | |
SG11201701297WA (en) | Antibodies and chimeric antigen receptors specific for cd19 | |
HK1218421A1 (zh) | 抗胰高血糖素受體抗體和其使用方法 | |
IL257295B (en) | Chimeric antigen receptors, and T cells in which expression of a chimeric antigen receptor is measured | |
ZA201508068B (en) | Cd19 specific chimeric antigen receptor and uses thereof |